Journal
Clinical cancer research
Publication Date
5-1-2023
Volume
29
Issue
9
First Page
1719
Last Page
1729
Document Type
Open Access Publication
DOI
10.1158/1078-0432.CCR-22-2177
Rights and Permissions
Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, Suresh R, Ademuyiwa FO, Rigden C, Rearden TP, Clifton K, Weilbaecher K, Frith A, Tandra PK, Summa T, Haas B, Thomas S, Hernandez-Aya LF, Peterson LL, Wang X, Luo SJ, Zhou K, Du P, Jia S, King BL, Krishnamurthy J, Ma CX. Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2023 May 1;29(9):1719-1729. doi: 10.1158/1078-0432.CCR-22-2177 This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
Recommended Citation
Davis, Andrew A; Luo, Jingqin; Suresh, Rama; Ademuyiwa, Foluso O; Rigden, Caron; Rearden, Timothy P; Clifton, Katherine; Weilbaecher, Katherine; Frith, Ashley; Summa, Tracy; Haas, Brittney; Thomas, Shana; Hernandez-Aya, Leonel F; Peterson, Lindsay L; Ma, Cynthia X; and et al., "Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer." Clinical cancer research. 29, 9. 1719 - 1729. (2023).
https://digitalcommons.wustl.edu/oa_4/2009
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
